Projects Achievements | Latest News

  • HARMONY reaches milestone capturing data from 45,000 patients with blood cancers.

    HARMONY reaches milestone capturing data from 45,000 patients with blood cancers.

    The HARMONY Big Data Platform is collecting 45,000 anonymized patient records, becoming one of the largest of its kind in the world; The goal of HARMONY is to help drive the development of better therapies and improve care for patients with various hematologic malignancies; The HARMONY Alliance is a public-private partnership of more than 80 Partners and Associated Members funded by the Innovative Medicines Initiative for a period of 5 years (2017-2021). The European public-private partnership ‘HARMONY” announced today at the 24th Annual Congress of the European Hematology Association, that its innovative Big Data Platform has reached an important milestone …
  • Launch of the ROADMAP Data Cube

    Launch of the ROADMAP Data Cube

    SYNAPSE - in conjunction with the ROADMAP partners- has developed an interactive Data Cube in 3D, which has been launched today. The Cube offers a dynamic overview of the ‘landscape’ of data availability in Europe for Alzheimer’s disease (AD) research. It allows the visualisation of the different data sources and how they are able to capture different AD-outcomes together with their relevance for the different disease stages. Users can switch between the perspectives of people with dementia, carers and health professionals. Enabling the visualisation of the AD-related data availability in different types of European data sources and the intrinsic gaps, …
  • Moving Forward: First Data Transferred Into The HARMONY Big Data Platform

    Moving Forward: First Data Transferred Into The HARMONY Big Data Platform

    An important step in search of new methods of treatment of hematological Malignancies: HARMONY Partners Ulm University, Novartis and Erasmus University Medical Center uploaded research data into the HARMONY Big Data Platform. More Partners and Associated Members announce their readiness to contribute data from their sources. The HARMONY Alliance is a large public-private European Network of Excellence for Big Data in Hematology, established in January 2017 and funded by the Innovative Medicines Initiative (IMI). More info: Harmony News
  • DRIVE Pilot year report, 2017/18 season

    DRIVE Pilot year report, 2017/18 season

    This report presents the achievements and results of the first annual study in 2017–2018 about influenza vaccine effectiveness . The overarching objective of this year was to test the DRIVE governance model and the infrastructure, tools and procedures developed during the first year of the DRIVE project. Five study sites from four countries (Austria, Finland, Italy, and Spain) participated in this first pilot study. More Info: DRIVE report.
  • RESCEU Older Adults Clinical Study achieves complete recruitment

    RESCEU Older Adults Clinical Study achieves complete recruitment

    The Older Adults Clinical Study has recently become the first clinical study in RESCEU to achieve full recruitment rate, according to schedule and with the appropriate age distribution. The study focuses on Respiratory Syncytial Virus (RSV) in older adults aged 60 years and above, and is part of the 4 Clinical Studies conducted by RESCEU across Europe (Birth cohort study, Infant case-control study, Older adults study and Chronic Obstructive Pulmonary Disease (COPD) study), to address the lack of knowledge on the burden of RSV in certain populations and provide substantial insights on the impact of RSV on health systems and …
  • EPAD passes the mark of 1,000 participants for its Longitudinal Cohort Study

    EPAD passes the mark of 1,000 participants for its Longitudinal Cohort Study

    The EPAD Longitudinal Cohort Study has recruited its 1,000thparticipant at the University of Oxford (UK) this 21st September on World Alzheimer’s Day. EPAD is one of the world leading dementia prevention studies, led from the University of Edinburgh. It is a Europe-wide collaboration aiming to improve the understanding of the early stages of Alzheimer’s disease. The EPAD project offers a unique platform for testing and developing preventative treatments for Alzheimer’s dementia. EPAD is set up to recruit from existing cohort studies as well as clinics across Europe. EPAD has established the first pan-European register including more than 30,000 research participants aged …
  • The iPiE Summary Database Search (iPiE*Sum) is launched

    The iPiE Summary Database Search (iPiE*Sum) is launched

    The overall aim of iPiE is to is to develop frameworks that utilize information from toxicological studies, pharmacological mode of action and in silico models to support more intelligent environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals for full environmental risk assessment and/or environmental (bio) monitoring. The iPiE Summary Database Search (iPiE*Sum) provides high level summarised access to the properties, environmental fate characteristics and ecotoxicity of APIs, which are collected during the course of the iPiE project from 2015 to 2018. iPiE*Sum is a web-based application conceived as a service to inform what studies have been performed by pharmaceutical companies for the approved …
  • RESCEU presented at the EMA Vaccine Working Party Meeting

    RESCEU presented at the EMA Vaccine Working Party Meeting

    RESCEU Work Package 2 representatives met with the EMA Vaccine Working Party (VWP) on June 7th at the EMA in London, as part of the RESCEU efforts for establishing continuous communication and collaboration with Regulatory Bodies. RESCEU representatives and EMA VWP members agreed that Work Package 2 outputs will be of importance to the EMA as they will: highlight target groups for interventions, inform research investment prioritisation, inform the design of clinical trials (such as by aiding in the selection of appropriate outcomes and case/severity definitions), and produce “baseline” burden data that will help assess the impact of future interventions. …
  • AMYPAD diagnostic and patient management study enrols its first research participant

    AMYPAD diagnostic and patient management study enrols its first research participant

    The members of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) initiative proudly announced the recruitment of its first research participant today. The first participant was recruited in Geneva, Switzerland, within the diagnostic and patient management sub-study (DMPS) of the AMYPAD project. In this clinical study, researchers aim to include subjects suspected of possible Alzheimer’s disease and determine the usefulness of β-amyloid imaging as a diagnostic marker for Alzheimer’s disease. The study will involve people with dementia, but also subjects with mild cognitive impairment (MCI) or subjective cognitive decline (SCD), and will study the impact of β-amyloid PET on both …
  • A Methodological Proposal from the ADVANCE Project published in Drug Safety journal

    A Methodological Proposal from the ADVANCE Project published in Drug Safety journal

    The ADVANCE project aspires to develop a blueprint for a framework capable of rapidly delivering reliable data on the benefits and risks of vaccines. Data on vaccine-preventable diseases and adverse reactions to vaccines exist in many places in diverse formats of healthcare databases. The ADVANCE consortium aims to identify and profile data sources capable of yielding rapid access to information. A web application - an interactive dashboard that allows near real-time monitoring of vaccine coverage and pre-specified health benefits has been developed by ADVANCE partners. In a paper "Benefit–Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE …
  • The ROADMAP consortium publishes its second article – a systematic review protocol

    The ROADMAP consortium publishes its second article – a systematic review protocol

    The ROADMAP project provides the foundation for an integrated data environment and framework for real-world evidence in Alzheimer’s disease. This includes the development of consensual key outcome measures and enabling data integration tools for dataset characterisation and outcome classification, as well as guidelines on the handling and interpretation of RWE data. Identifying the real-world outcomes of AD that matter most to key stakeholders will help ensure that future treatments effectively improve the lives of those affected. As to obtain a set of real-world AD outcomes, a systematic literature review on quality of life of people with predementia and dementia and their caregivers was conducted. …
  • The University of Oxford, a TransQST consortium partner, won the 2017 NC3Rs Prize

    The University of Oxford, a TransQST consortium partner, won the 2017 NC3Rs Prize

    The UK-based National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) awarded its 2017 International prize to the team of Computer of Science Department (University of Oxford), for their research which developed original in silico model that predicts the clinical risk of drug-induced side effects for the heart with higher accuracy than animal experiments (see Article). The software was developed within the framework of the TransQST project. This excellent work will be implemented to address the TransQST challenges in the field of modeling simulation to support drug development. TransQST aims to develop novel computational approaches using …
  • EPAD reaches an important milestone

    EPAD reaches an important milestone

    European Prevention of Alzheimer's Dementia is a collaborative research initiative to improve the chance of successfully preventing Alzheimer’s dementia. The Europe-wide study aims to recruit thousands of people, of which many may be selected to participate in trials to test new treatments for the prevention of Alzheimer’s dementia.The EPAD Longitudinal Cohort Study began recruitment in May 2016 and this month the EPAD project has reached an important milestone: 500 research participant screened. Currently, the EPAD LSC is recruiting at 12 study sites, and several new trial delivery centers will be open in the following weeks. More about EPAD at http://ep-ad.org/.
  • Launch of the “Big Data” platform of the Harmony project

    Launch of the “Big Data” platform of the Harmony project

    HARMONY, an IMI-JU funded project, coordinated by The Institute for Biomedical Research of Salamanca, launches a “Big Data” platform that will enable hematologic cancers research. The platform, led by the Spanish partner GMW, will integrate databases of more than 10.000 anonymous patients and will be able to provide information about the best treatment for each hematologic disease, paving the way for personalized medicine. The launch of the platform had a great coverage in Spanish media. Cuatro, Diariomedico, Ileon are only a few of the Spanish mass media that reported the set-up of the platform. More about the HARMONY project at https://www.harmony-alliance.eu/ 
  • Latest version of the histopathology ontology has been released

    Latest version of the histopathology ontology has been released

    eTOX, an IMI-JU 1 funded project ended in December 2016. One major achievement of the eTOX project was the development of common ontologies. Histopathology Ontology, that allows mapping of the histological lesions in toxicological studies. This ontology complements the OntoBrowser tool, developed to manage ontologies and controlled terminologies. Both the Histopathology Ontology and the OntoBrowser have  been developed by Novartis. Both tools would serve as an important legacy to be further used within eTRANSAFE, an IMI-2 project recently started. More info on histopathology ontology at eTRANSAFE
  • HARMONY’s Big Data platform presented at the 2nd General Assembly

    HARMONY’s Big Data platform presented at the 2nd General Assembly

    The Project’s 2nd GA was held in Berlin, Germany, on the 23rd and 24th of October 2017 where the most advanced technology in data sharing was presented to contribute to a better understanding of hematologic cancers. Public and private organizations will contribute data on most hematologic cancers. The use of a common data model will allow to conduct analysis at an unprecedented scale. Synapse is member of the HARMONY’s Project Management Office, and supports the Executive and Steering Committees in facilitating collaboration and ensuring the effective contribution from all partners in this ambitious project. Read more at: press release More …

Recent Tweets

Follow Us

CONTACT DETAILS

Tel: +34 93 300 6061 | info@synapse-managers.com
Diputación 237, Ático 3ª. 08007 Barcelona (Spain)
Velázquez, 94. 1º Planta, 28006 Madrid (Spain)

Click to open a larger map

 
 

HIGHLIGHTS

EU-ADR Alliance
A federated collaborative framework for drug safety studies

Synapse Flyer
A quick overview of our Background and Services (PDF format)